

Jean-Marie Bard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6761401/jean-marie-bard-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72
papers

3,756
citations

24
h-index

61
g-index

76
ext. papers

4,102
ext. citations

4.5
avg, IF

4.26
L-index

#	Paper	IF	Citations
72	Alimentation glucidolipidique et maladies cardio-vasculaires. <i>Actualites Pharmaceutiques</i> , 2021 , 60, 28-33		
71	Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study. <i>Nutrients</i> , 2021 , 13,	6.7	5
70	The intratumoral microbiome: Characterization methods and functional impact. <i>Cancer Letters</i> , 2021 , 522, 63-79	9.9	1
69	848-P: Totum-63 Lowers Fasting Glycemia in Subjects with Prediabetes: A Phase 2A Clinical Trial. <i>Diabetes</i> , 2020 , 69, 848-P	0.9	1
68	Centre de Ressources Biologiques-Tumorothèque: Bioresources and Associated Clinical Data Dedicated to Translational Research in Oncology at the Institut de Cancérologie de l'Ouest, France. <i>Open Journal of Bioresources</i> , 2020 , 7,	0.9	5
67	Effect of milk fat on LDL cholesterol and other cardiovascular risk markers in healthy humans: the INNOVALAIT project. <i>European Journal of Clinical Nutrition</i> , 2020 , 74, 285-296	5.2	4
66	New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients. <i>Future Science OA</i> , 2019 , 5, FSO374	2.7	0
65	Targeting bioactive compounds in natural extracts - Development of a comprehensive workflow combining chemical and biological data. <i>Analytica Chimica Acta</i> , 2019 , 1070, 29-42	6.6	12
64	Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients. <i>Diabetes and Metabolism</i> , 2019 , 45, 573-581	5.4	12
63	Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study. <i>Journal of Lipid Research</i> , 2018 , 59, 892-900	6.3	21
62	Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2018 , 41, 13-24	7.2	40
61	Microalgae in Human Health: Interest as a Functional Food 2018 , 211-226		4
60	Leptin and adiponectin as new markers of undernutrition in cancer. <i>Clinical Biochemistry</i> , 2017 , 50, 525-533		4
59	Intestinal Proportion of Blautia sp. is Associated with Clinical Stage and Histoprognotic Grade in Patients with Early-Stage Breast Cancer. <i>Nutrition and Cancer</i> , 2017 , 69, 267-275	2.8	66
58	Interindividual variability in the cholesterol-lowering effect of supplementation with plant sterols or stanols. <i>Nutrition Reviews</i> , 2017 , 75, 134-145	6.4	14
57	Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity. <i>Anticancer Research</i> , 2017 , 37, 5495-5498	2.3	5
56	Risques comparés des stérols végétaux et du cholestérol alimentaire. <i>Pratiques En Nutrition</i> , 2017 , 13, 21-24	0	

55	LXR Activation Down-regulates Lipid Raft Markers FLOT2 and DHHC5 in MCF-7 Breast Cancer Cells. <i>Anticancer Research</i> , 2017 , 37, 4067-4073	2.3	8
54	Seaweeds in Human Health 2016 , 319-367		21
53	Les aliments fonctionnels contenant des phytostérols ou des phytostanols : quels bénéfices, quels risques?. <i>Pratiques En Nutrition</i> , 2016 , 12, 32-35	0	1
52	Effect of phytosterols/stanols on LDL concentration and other surrogate markers of cardiovascular risk. <i>Diabetes and Metabolism</i> , 2015 , 41, 69-75	5.4	13
51	Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence. <i>Clinical Biochemistry</i> , 2015 , 48, 1181-3	3.5	13
50	Phytostérols : un point sur les recommandations de l'ANSES. <i>Cahiers De Nutrition Et De Dietetique</i> , 2015 , 50, 209-214	0.2	2
49	Phytostérols : un point sur les recommandations de l'ANSES. <i>OCL - Oilseeds and Fats, Crops and Lipids</i> , 2015 , 22, D205	1.5	1
48	Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. <i>European Journal of Nutrition</i> , 2013 , 52, 1843-52	5.2	23
47	A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. <i>International Journal of Food Sciences and Nutrition</i> , 2013 , 64, 882-9	3.7	26
46	A new, validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-fluorouracil, doxorubicin and cyclophosphamide in surface contamination. <i>Journal of Analytical Toxicology</i> , 2013 , 37, 433-9	2.9	16
45	Macrophage apolipoprotein E and proliferation of MCF-7 breast cancer cells: role of LXR. <i>Anticancer Research</i> , 2013 , 33, 3783-9	2.3	16
44	Evaluation of digestive tolerance of a soluble corn fibre. <i>Journal of Human Nutrition and Dietetics</i> , 2012 , 25, 488-96	3.1	9
43	Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence. <i>Clinical Biochemistry</i> , 2012 , 45, 1503-5	3.5	21
42	Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1672-8	1.6	26
41	Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 393-9	1.6	6
40	LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis. <i>Anticancer Research</i> , 2012 , 32, 3007-13	2.3	60
39	A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 705-10	3.2	12
38	Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. <i>Cerebrovascular Diseases</i> , 2010 , 30, 252-9	3.2	45

37	Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. <i>Metabolism: Clinical and Experimental</i> , 2009 , 58, 784-9	12.7	8
36	Unusual sterolic mixture, and 24-isopropylcholesterol, from the sponge <i>Ciocalyptha</i> sp. reduce cholesterol uptake and basolateral secretion in Caco-2 cells. <i>Journal of Cellular Biochemistry</i> , 2009 , 106, 659-65	4.7	6
35	Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia. <i>Lipids in Health and Disease</i> , 2008 , 7, 35	4.4	28
34	Plasma cystatin-C and development of coronary heart disease: The PRIME Study. <i>Atherosclerosis</i> , 2006 , 185, 375-80	3.1	86
33	Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 980-8	12.7	57
32	Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. <i>Antiviral Therapy</i> , 2006 , 11, 361-70	1.6	3
31	Association of Apolipoproteins C3 and E with Metabolic Changes in HIV-Infected Adults Treated with a Protease-Inhibitor-Containing Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 361-370	1.6	7
30	Sex hormone-binding globulin is a major determinant of the lipid profile: the PRIME study. <i>Atherosclerosis</i> , 2005 , 179, 369-73	3.1	55
29	Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. <i>Atherosclerosis</i> , 2003 , 170, 169-76	3.1	127
28	C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 1255-61	9.4	296
27	Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1155-61	9.4	144
26	Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. <i>Atherosclerosis</i> , 2002 , 163, 377-84	3.1	170
25	Quantitative Measurement of Lipoprotein Particles Containing Both Apolipoprotein AIV and Apolipoprotein B in Human Plasma by a Noncompetitive ELISA. <i>Clinical Chemistry</i> , 2002 , 48, 884-890	5.5	6
24	Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. <i>Diabetes/Metabolism Research and Reviews</i> , 2000 , 16, 2-7	7.5	44
23	Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME study. <i>Journal of Human Hypertension</i> , 2000 , 14, 511-8	2.6	11
22	An innovative, high quality and search window independent motion estimation algorithm and architecture for MPEG-2 encoding. <i>IEEE Transactions on Consumer Electronics</i> , 2000 , 46, 697-705	4.8	15
21	Plasma cholesterol and endogenous cholesterol synthesis during refeeding in anorexia nervosa. <i>Clinica Chimica Acta</i> , 2000 , 294, 45-56	6.2	27
20	The relationship between apolipoprotein AI-containing lipoprotein fractions and environmental factors: the prospective epidemiological study of myocardial infarction (PRIME study). <i>Atherosclerosis</i> , 2000 , 152, 399-405	3.1	18

19	Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. <i>Atherosclerosis</i> , 1997 , 131, 257-62	3.1	16
18	Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM study. <i>European Journal of Clinical Investigation</i> , 1997 , 27, 242-7	4.6	2
17	The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. <i>Atherosclerosis</i> , 1996 , 126, 299-303	3.1	146
16	Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. <i>American Journal of Cardiology</i> , 1995 , 76, 65A-70A	3	5
15	Location of probucol in lipoproteins inferred from compositional analysis of lipoprotein particles. An in-vitro study. <i>Journal of Pharmacy and Pharmacology</i> , 1994 , 46, 797-800	4.8	4
14	Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group. <i>American Journal of Medicine</i> , 1994 , 96, 32S-36S	2.4	12
13	Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. <i>American Journal of Medicine</i> , 1994 , 96, 45S-54S	2.4	18
12	HDL particle measurements: impact for diagnosis and therapy. <i>Clinical Biochemistry</i> , 1993 , 26, 65-8	3.5	7
11	Identification of apoB-containing lipoprotein families in NIDDM. <i>Diabetes</i> , 1992 , 41 Suppl 2, 18-25	0.9	24
10	A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. <i>Metabolism: Clinical and Experimental</i> , 1992 , 41, 498-503	12.7	73
9	Isolation and characterization of two sub-species of Lp(a), one containing apo E and one free of apo E. <i>Lipids and Lipid Metabolism</i> , 1992 , 1127, 124-30		27
8	Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. <i>Nature</i> , 1992 , 359, 641-4	50.4	1670
7	apoB-containing lipoprotein particles as risk factors for coronary artery disease. <i>Advances in Experimental Medicine and Biology</i> , 1991 , 285, 299-309	3.6	12
6	Lipoprotein particles in homozygous familial hypercholesterolemic patients treated with portacaval shunt and LDL apheresis. <i>Clinica Chimica Acta</i> , 1990 , 193, 165-79	6.2	4
5	Apolipoprotein B immunochemical heterogeneity in dialysed patients with chronic renal failure and patients with coronary artery stenosis. <i>American Journal of Nephrology</i> , 1989 , 9, 110-4	4.6	5
4	Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. <i>Atherosclerosis</i> , 1989 , 78, 167-82	3.1	55
3	Apolipoproteins in human amniotic fluid: concentrations, isoforms and polymorphism. <i>Gynecologic and Obstetric Investigation</i> , 1989 , 28, 127-31	2.5	1
2	Quantification of human apolipoprotein E in plasma and lipoprotein subfractions by a non-competitive enzyme immunoassay. <i>Clinica Chimica Acta</i> , 1987 , 163, 245-56	6.2	24

- 1 Effect of fenofibrate treatment on type III hyperlipoproteinemia. *American Journal of Medicine*, **1987**, 83, 71-4 2.4 28